Previous 10 | Next 10 |
Phase 3 PaTHway Trial top-line results demonstrated potential of TransCon™ PTH to become the first parathyroid replacement therapy for adults with hypoparathyroidism TransCon PTH U.S. FDA regulatory submission on track for Q3 and EU MAA for Q4 2022 Increasing up...
Ascendis Pharma (ASND) is scheduled to announce Q1 earnings results on Wednesday, May 11th, after market close. The consensus EPS Estimate is -$2.16 and the consensus Revenue Estimate is $4.85M (+592.9% Y/Y). Over the last 3 months, EPS estimates have seen 2 upward revisions and 2 downward. R...
COPENHAGEN, Denmark, May 09, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company is scheduled to attend the BofA Securities 2022 Healthcare Conference. Company executives will participate in a fireside chat hosted by BofA on Thursday, May 12. ...
Shares have lost nearly 40% of their value year to date. I provide a recap of the bullish thesis, which has strengthened considerably with conclusive phase 3 data for TransCon PTH. For hypoparathyroidism, there are over 75k patients in the US alone and quality of life benefits poi...
COPENHAGEN, Denmark, May 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call and live webcast on Wednesday, May 11, 2022 at 4:30 p.m. Eastern Time (ET) to review its first quarter 2022 financial results and provide a b...
New data highlights include: - Phase 3 open-label extension study data for growth hormone-deficient children treated for 2.5 years with TransCon TM hGH - Initial findings from research on comorbidities associated with adult growth hormone deficiency ...
Look for surprise values in underpriced stocks. Not the story issues being ballyhooed by touts and the media – everyone knows them. The hidden values are ones found by experienced professional researchers who know the details of industry group issues and their special strengths...
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
Ascendis Pharma (NASDAQ:ASND) has priced of its offering of $500M of 2.25% convertible senior notes due 2028 in a private offering to qualified institutional buyers. The issuance and sale of the notes are scheduled to settle on March 29, 2022. Initial purchasers are granted over-allotment of ...
COPENHAGEN, Denmark, March 24, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candidates that address unmet medical needs, today announced the pricing of its offering of US$500...
News, Short Squeeze, Breakout and More Instantly...
— Rollout of YORVIPATH ® initiated in Germany and Austria, with an estimated 55 doctors writing prescriptions and ~100 patients receiving commercial product as of March 31 — TransCon™ PTH (palopegteriparatide) PDUFA date of May 14, 2024, for ...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
2024-04-29 11:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...